13. ADDITIONAL INCLUSION CRITERIA FOR BRAF and RAS MUTATION (COHORTS 1 and 2): Ability to swallow pills. Patients may be assigned to bevacizumab + atezolizumab cohort 3 or taxane + atezolizumab cohort 4 (in this order of preference) if they are unable to swallow pills